Quinolones are a class of synthetic antibiotics that kill bacteria by sabotaging the enzymes responsible for managing bacterial DNA. The first quinolone, nalidixic acid, was discovered in the early 1960s as a byproduct of research on the antimalarial drug chloroquine, and it worked only against a narrow range of bacteria causing urinary tract infections.1PubMed Central. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity Over the following decades, chemists modified the original molecule to create far more powerful versions, and today the quinolone family includes some of the most widely prescribed antibiotics in the world. That success, though, has come with serious safety concerns, growing bacterial resistance, and regulatory restrictions that have reshaped how doctors use these drugs.
From Nalidixic Acid to Modern Fluoroquinolones
The story of quinolones is essentially a story of chemical tinkering. Nalidixic acid had a limited spectrum and could only reach useful concentrations in urine, which made it a niche drug for simple bladder infections. Researchers discovered that adding a fluorine atom at position 6 of the quinolone ring, along with other modifications at positions 1, 7, and 8, dramatically improved the drug’s potency, its ability to penetrate tissues, and the range of bacteria it could kill.2PubMed Central. Mechanism of action of and resistance to quinolones The first of these “fluoroquinolones” was norfloxacin, which arrived in the 1980s. Ciprofloxacin followed shortly after, offering strong activity against gram-negative bacteria and a number of unusual pathogens, decent absorption when taken by mouth, and good tissue distribution.3PubMed. The fluoroquinolone antibacterials: past, present and future perspectives
Later generations pushed the spectrum even wider. Levofloxacin and moxifloxacin, for instance, gained significantly better activity against gram-positive bacteria like the pneumococcus that causes community-acquired pneumonia. In head-to-head comparisons against pneumococcal isolates, ciprofloxacin is the least active of the group, while moxifloxacin and similar agents are consistently more bactericidal.4PubMed. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model That is why you will hear ciprofloxacin called a good “gram-negative” drug and moxifloxacin called a “respiratory” fluoroquinolone. The choice of which one a doctor reaches for depends heavily on where the infection is and which organisms are likely causing it.
How Quinolones Kill Bacteria
Bacteria have two essential enzymes that manage the coiling and uncoiling of their DNA during replication: DNA gyrase and topoisomerase IV. Without these enzymes working properly, a bacterium cannot copy its chromosome, and it dies. Quinolones exploit this by binding to these enzymes while they are attached to DNA, effectively converting the cell’s own machinery into a weapon against it.5PubMed Central. Mechanism of quinolone action and resistance
The process involves two steps. First, the drug locks onto the enzyme-DNA complex, forming a stable but reversible structure that stalls the enzyme in place. Second, and more lethally, the trapped complex releases double-strand breaks in the bacterial chromosome. These breaks are catastrophic for the cell.6PubMed. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance Because the drug has two different enzyme targets in most bacteria, a single point mutation in one enzyme often is not enough to confer resistance. The bacterium would need to overcome protection in both targets simultaneously, which is part of why quinolones were so durably effective for years.
Taking Them Correctly Matters More Than You Might Think
Fluoroquinolones are “concentration-dependent” killers, meaning the higher the drug concentration relative to what the bacterium can tolerate, the faster it dies. The key metric clinicians care about is how much total drug exposure occurs over a 24-hour period compared to the minimum concentration needed to inhibit a given bacterium.7PubMed Central. Pharmacokinetic and Pharmacodynamic Principles of Anti-Infective Dosing In practical terms, this means taking your full prescribed dose on schedule is critical. Skipping doses or stopping early does not just risk undertreating the infection; it creates exactly the kind of sublethal drug exposure that gives resistant mutants a chance to survive and multiply.
One of the most common ways people accidentally sabotage their fluoroquinolone therapy is by taking the pill alongside certain minerals. Antacids containing aluminum or magnesium, calcium supplements, iron tablets, and even some multivitamins contain metal ions that bind tightly to fluoroquinolones in the gut. This chelation can slash the amount of drug that actually gets absorbed into the bloodstream, sometimes to the point where it no longer reaches effective levels.8PubMed Central. Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant? Pharmacists typically advise spacing these products at least two hours before or six hours after the fluoroquinolone dose. It is a simple step that makes a real difference in whether the antibiotic works.
Side Effects and Why the FDA Strengthened Its Warnings
Most people who take a short course of a fluoroquinolone experience nothing worse than mild nausea or diarrhea. But this drug class carries an unusually broad range of serious side effects that can affect tendons, nerves, the heart, blood sugar, and the aorta. The cumulative weight of these risks is what led the U.S. Food and Drug Administration in 2016 to add its strongest “black box” warning, recommending that fluoroquinolones be avoided for uncomplicated infections like simple urinary tract infections, sinus infections, and bronchitis flare-ups when safer alternatives exist.9PubMed. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals
Tendons and Connective Tissue
Fluoroquinolone-associated tendon damage, particularly Achilles tendon rupture, is probably the best-known serious side effect. The underlying problem appears to involve collagen, the structural protein that gives tendons their strength. Fluoroquinolones reduce the production of collagen and related structural molecules in tendon cells, and they also disrupt the enzymes that remodel collagen after injury.10PubMed Central. Fluoroquinolone-Induced Achilles Tendon Damage: Structural and Biochemical Insights into Collagen Type I Alterations The risk is highest in people over 60, those taking corticosteroids at the same time, and organ transplant recipients. But isolated cases occur in otherwise healthy younger adults too, sometimes weeks after finishing the course.
The same collagen-disrupting mechanism extends beyond tendons. The aorta, the body’s largest artery, depends on collagen and elastin for its structural integrity. Fluoroquinolones may upregulate enzymes called matrix metalloproteinases that break down these structural proteins in the arterial wall, weakening it.11JAMA Internal Medicine. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone Multiple meta-analyses have found that current fluoroquinolone use is associated with roughly double the risk of aortic aneurysm or aortic dissection compared to non-use.12PubMed Central. Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis A separate meta-analysis found a similar signal, with current use linked to an odds ratio of about 2.25 for aortic aneurysm and about 2.79 for aortic dissection.13PubMed. Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis These are still rare events in absolute terms, but they are life-threatening when they happen, and the association is strong enough to matter for patients who already have aortic risk factors.
The Nervous System and Heart
Neurological side effects span a wide range. Common complaints include headaches, dizziness, and difficulty sleeping. Less common but more alarming reactions include confusion, psychosis, and seizures.14PubMed Central. Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice Some patients report peripheral neuropathy, a tingling or burning sensation in the hands and feet, that can persist long after the drug is stopped. The FDA has flagged this specifically as a reason to discontinue therapy immediately if symptoms appear.
On the cardiac side, fluoroquinolones can prolong the QT interval on an electrocardiogram by blocking potassium channels in the heart. This is likely a class-wide effect, though the degree varies between drugs.15PubMed Central. Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones Moxifloxacin carries the greatest risk; one study found it prolonged the corrected QT interval by about 6 milliseconds after a standard seven-day course, while ciprofloxacin and levofloxacin had no measurable effect.16PubMed Central. Effects of three fluoroquinolones on QT analysis after standard treatment courses The overall risk of dangerous heart rhythm disturbances is small, but doctors are cautious about prescribing these drugs to patients who already have QT prolongation, are taking other QT-prolonging medications, or have electrolyte imbalances.17PubMed. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications
Blood Sugar Swings
Some fluoroquinolones can cause both dangerously low and dangerously high blood sugar, sometimes in the same patient during a single treatment course. The low blood sugar (hypoglycemia) tends to happen early and appears to result from the drug stimulating insulin release from pancreatic cells by blocking potassium channels in those cells.18PubMed. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels High blood sugar (hyperglycemia) tends to appear several days into therapy, and the exact mechanism is less clear, though it may involve counter-regulatory hormones.19PubMed. Dysglycaemias and fluoroquinolones This is a particular concern for people with diabetes who are already managing their blood sugar with medication. One older fluoroquinolone, gatifloxacin, was eventually pulled from markets in several countries largely because of the severity and frequency of these blood sugar disturbances.
How Bacteria Become Resistant
Resistance to quinolones has grown steadily since the drugs became widely used. Bacteria have evolved several strategies to survive exposure, and these strategies often stack on top of one another in the same organism, producing highly resistant strains.
The most common route involves mutations in the genes encoding the drug’s targets, DNA gyrase and topoisomerase IV. Specific regions of these genes, called quinolone resistance-determining regions, accumulate point mutations that change the shape of the drug’s binding site just enough to weaken its grip. In studies of resistant gut bacteria, it is common to find double mutations in the gyrase gene combined with a mutation in the topoisomerase IV gene.20PubMed Central. Mutations in the quinolone resistance-determining regions of gyrA and parC in Enterobacteriaceae isolates from Brazil Each additional mutation raises the level of resistance, so an organism with mutations in both targets can survive drug concentrations many times higher than the original sensitive strain.21PubMed Central. QRDR mutations, efflux system & antimicrobial resistance genes in enterotoxigenic Escherichia coli isolated from an outbreak of diarrhoea in Ahmedabad, India
A second category of resistance is more insidious because it is portable. Bacteria can carry small circular DNA elements called plasmids that encode resistance genes capable of jumping between unrelated bacterial species. Three plasmid-borne mechanisms have been identified for quinolone resistance:
- Qnr proteins: These belong to a family of protective proteins that physically shield gyrase and topoisomerase IV from quinolone attack. Several variants exist, and new ones continue to be discovered.
- Acetylation by AAC(6′)-Ib-cr: This is a modified form of an enzyme that normally inactivates a different antibiotic class. The variant can chemically modify certain fluoroquinolones like ciprofloxacin and norfloxacin, reducing their activity.
- Efflux pumps: Plasmid-encoded pumps like QepA actively expel the drug from the bacterial cell before it can reach its target.
These plasmid-mediated mechanisms on their own usually provide only low-level resistance, not enough to make the bacterium fully resistant by clinical breakpoints. But they lower the bar, making it easier for the cell to acquire the target-site mutations that push it over the edge into full resistance.22PubMed Central. Plasmid-mediated quinolone resistance In a surveillance study from Norway and Sweden, the prevalence of these plasmid resistance genes was substantially higher among bacteria that also produced extended-spectrum beta-lactamases, enzymes that confer resistance to another major antibiotic class. This overlap means the same organism can become resistant to multiple drug families simultaneously.23PubMed. Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden
A third mechanism involves chromosomally encoded efflux pumps that bacteria already possess for other purposes. When overexpressed, pumps like AcrAB and OqxAB can contribute to ciprofloxacin resistance in clinical isolates of bacteria like Klebsiella.24PubMed. Overexpression of Efflux Pumps AcrAB and OqxAB Contributes to Ciprofloxacin Resistance in Clinical Isolates of K. pneumonia The combined effect of all these mechanisms is that resistance to fluoroquinolones is now widespread in many common pathogens, limiting the usefulness of drugs that were once considered reliable go-to choices.
Quinolones in Agriculture and the Environment
The resistance problem does not stay within hospital walls. Fluoroquinolones have been used extensively in veterinary medicine, especially in poultry farming. Enrofloxacin, a veterinary fluoroquinolone, was widely administered to chickens, and research has connected its use to the spread of fluoroquinolone-resistant bacteria through the food chain. Studies from the Netherlands found that after enrofloxacin was introduced in poultry, quinolone-resistant Campylobacter began appearing in both chickens and humans, with the poultry industry identified as the likely source.25Journal of Antimicrobial Chemotherapy. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine Human infections with fluoroquinolone-resistant Campylobacter have been increasingly linked to poultry consumption.26Clinical Infectious Diseases. Fluoroquinolone-Resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: A Public Health Success Story The FDA eventually banned enrofloxacin use in poultry in the United States in 2005, one of the more decisive regulatory actions taken to limit agricultural contributions to antibiotic resistance.
Beyond farms, fluoroquinolones have become persistent environmental contaminants. Because they are not fully metabolized in the body, active drug ends up in wastewater from both human and animal sources. Surveys across more than 30 countries have found widespread fluoroquinolone contamination in surface water, with ciprofloxacin and norfloxacin being the most common pollutants. These drugs are relatively stable in the environment, creating a state of “pseudo-persistence” where continuous discharge maintains detectable levels even though individual molecules do degrade over time.27PubMed Central. Occurrence, Bioaccumulation, Metabolism and Ecotoxicity of Fluoroquinolones in the Aquatic Environment: A Review The ecological consequences are still being mapped, but any sustained low-level antibiotic in a waterway creates selection pressure that favors resistant bacteria in the environment.
When Fluoroquinolones Are Still the Right Choice
The FDA warnings and stewardship efforts have not made quinolones obsolete. They remain first-line therapy for several serious infections where alternatives are limited or inferior. Complicated urinary tract infections and certain intra-abdominal infections still warrant fluoroquinolone use in many cases. Ciprofloxacin is the standard post-exposure prophylaxis for anthrax, a role tested extensively after the 2001 bioterror attacks. Modeling work has shown that a ciprofloxacin regimen could clear the anthrax spore burden in most patients in about 35 days, which led some researchers to suggest that the traditional 60-day course might be longer than necessary.28PubMed Central. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Newer fluoroquinolones like delafloxacin have shown strong activity against anthrax strains, including those resistant to ciprofloxacin, particularly in the acidic conditions found at sites of infection.29Journal of Antimicrobial Chemotherapy. Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis
The key shift in medical thinking is not that fluoroquinolones are too dangerous to use, but that their risk profile means they should be reserved for infections where simpler antibiotics would not work as well. A straightforward bladder infection in an otherwise healthy person does not warrant the tendon, nerve, and cardiovascular risks when trimethoprim-sulfamethoxazole or nitrofurantoin will do the job. A severe pneumonia requiring hospitalization, a complicated kidney infection, or post-exposure anthrax prophylaxis is a different calculation entirely.
New Drugs Targeting the Same Enzymes
The growing resistance problem has spurred work on new antibiotics that attack the same bacterial enzymes, gyrase and topoisomerase IV, but bind to different sites on those proteins so that existing quinolone resistance mutations do not block them. Two such drugs, gepotidacin and zoliflodacin, were approved for human use in 2025, representing the first entirely new antibiotic classes targeting these enzymes in decades.30PubMed Central. Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks Because they exploit a different binding pocket on the enzyme-DNA complex, they remain active against bacteria that have accumulated the classic quinolone-resistance mutations.
Another line of research involves compounds called novel bacterial topoisomerase inhibitors, or NBTIs, which bind to a pocket at the interface where two copies of gyrase meet. Structural studies have confirmed that this binding site is distinct from the one quinolones use, meaning cross-resistance is minimal. These compounds are active against multidrug-resistant bacteria in laboratory testing.31PubMed Central. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site Whether they succeed clinically remains to be seen, but they represent a promising strategy: rather than abandoning a validated bacterial vulnerability, find new ways to exploit it.
Quinolone Scaffolds Beyond Antibiotics
An area of research that most people are unaware of is the exploration of quinolone-based chemical scaffolds for anticancer activity. The same core ring structure that makes quinolones effective antibiotics can, with appropriate modifications, interact with human enzymes and signaling pathways relevant to cancer. Researchers have reported quinolone derivatives that act through multiple anticancer mechanisms, including inhibiting human topoisomerases, triggering programmed cell death in tumor cells, arresting cell division, and interfering with growth-signaling networks.32European Journal of Medicinal Chemistry. 2- and 4-quinolones as emerging anticancer scaffolds: Recent synthetic developments, SAR insights, and mechanistic perspective This work is still in its early stages, largely confined to lab studies and computational modeling, but it illustrates how a chemical framework originally designed to poison bacterial enzymes can be repurposed for entirely different therapeutic goals. The quinolone ring, in other words, has turned out to be a remarkably versatile starting point for drug design, and its medical story is still being written.